Punctal plugs and methods of delivering therapeutic agents

• US 8,753,666 B2
• Filed: 01/30/2008
• Issued: 06/17/2014
• Est. Priority Date: 01/31/2007
• Status: Active Grant

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Research Limited (Nestle SA)
• Inventors: Rodstrom, Theron R., Smith, Larry II, Tian, Youqin, Marsh, David Allen, Weiner, Alan L., Bakshi, Shivalik
• Primary Examiner(s): Kwon, Brian-Yong
• Assistant Examiner(s): Stevens, Mark V
• Application Number:
  US12/022,520
• Publication Number:
  US 20080181930A1
• Time in Patent Office: 2,330 Days
• Field of Search: None
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating on the outer surface of the body; and (c) one or more pores extending from the outer surface of the parylene coating to the outer surface of the body.

Claims

1. A drug-delivery device comprising:

(a) a body comprising a matrix of a silicone and an ophthalmic drug dispersed throughout the matrix, the body being a monolithic structure having an outer surface and being configured to be inserted through a punctal aperture and positioned in a punctum or lacrimal canaliculus;

(b) a parylene coating covering the outer surface of the body, the parylene coating being substantially impermeable to the drug; and

(c) at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the body;

wherein the parylene coating covers all surfaces of the outer surface of the body with the exception of the surface of the body exposed by the at least one pore;

wherein the ophthalmic drug is a glaucoma medicament.

2. The drug-delivery device of claim 1, wherein the body comprises:

(a) a shaft portion having a first end and a second end, wherein the shaft portion is configured for insertion through a punctal aperture and positioning in a punctum or lacrimal canaliculus;

(b) a head portion attached to the first end of the shaft portion, wherein the head portion is configured to rest on the exterior of the punctum; and

(c) a distal tip portion attached to the second end of the shaft portion.

3. The drug delivery device of claim 1, wherein the glaucoma medicament is a prostaglandin.

4. The drug-delivery device of claim 3 wherein the prostaglandin is cloprostenol, fluprostenol, latanoprost, travoprost, or unoprostone.

5. The drug delivery device of claim 3, wherein the concentration of the prostaglandin in the matrix is 0.5% to 15% by weight.

6. The drug delivery device of claim 3, wherein the concentration of the prostaglandin in the matrix is 1% to 10% by weight.

7. The drug-delivery device of claim 1, wherein the parylene coating is 1 μ

m to 20 μ

m thick.

8. The drug-delivery device of claim 1, wherein the parylene coating is 5 μ

m to 15 μ

m thick.

9. The drug-delivery device of claim 2, wherein the body further comprises a canalicular extension attached to the distal tip portion of the body, wherein the canalicular extension is configured for insertion through the punctal aperture and the punctum and positioning in the lacrimal canaliculus.

10. The drug-delivery device of claim 9, wherein the canalicular extension has a length L1 and the body has a length L2, wherein the ratio of the length L1 to the length L2 is 2:

1 to 10;

1.

11. The drug-delivery device of claim 9, wherein the canalicular extension is configured for positioning in both the lacrimal canaliculus and a nasolacrimal duct.

12. The drug delivery device of claim 2 wherein the at least one pore extends to the surface of the body at the head portion.

13. The drug delivery device of claim 1, wherein the glaucoma medicament is travoprost and wherein the silicone operates in conjunction with the at least one pore to release the travoprost at a therapeutically effective dose for period of 60 to 240 days.

14. The drug delivery devices of claim 1 wherein a length L1 of the canalicular extension is between 5 and 15 millimeter.

20. The drug-delivery device of claim 2, wherein the body further comprises a canalicular extension attached to the distal tip portion of the body, wherein the canalicular extension is configured for insertion through the punctal aperture and the punctum and positioning in the lacrimal canaliculus andwherein the canalicular extension has a length L1 and the body has a length L2, wherein the ratio of the length L1 to the length L2 is 2:

1 to 10;

1 and wherein the length L1 of the canalicular extension is between 5 and 15 millimeter.

21. The drug delivery device of claim 9 wherein the canalicular extension includes a stylus for providing increased stiffness to the canalicular extension.

23. The drug delivery device of claim 20 wherein the canalicular extension includes a stylus for providing increased stiffness to the canalicular extension.

15. A drug-delivery device comprising:

(a) a body comprising a matrix of a silicone and an ophthalmic drug dispersed throughout the matrix, the body having an outer surface and being configured to be inserted through a punctal aperture and positioned in a punctum or lacrimal canaliculus, wherein the body is a monolithic structure that includes;

i. a shaft portion having a first end and a second end, wherein the shaft portion is configured for insertion through a punctal aperture and positioning in a punctum or lacrimal canaliculus;

ii. a head portion attached to the first end of the shaft portion, wherein the head portion is configured to rest on the exterior of the punctum; and

iii. a distal tip portion attached to the second end of the shaft portion;

(b) a parylene coating covering the outer surface of the body, the parylene coating being substantially impermeable to the drug; and

(c) at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the head portion of the body;

wherein the parylene coating covers all surfaces of the outer surface of the body with the exception of the surface of the head portion exposed by the at least one pore;

wherein the ophthalmic drug is a glaucoma medicament.

16. The drug-delivery device of claim 15, wherein the glaucoma medicament is a prostaglandin.

17. The drug-delivery device of claim 15 wherein the body further comprises a canalicular extension attached to the distal tip portion of the body, wherein the canalicular extension is configured for insertion through the punctal aperture and the punctum and positioning in the lacrimal canaliculus and wherein the canalicular extension has a length L1 and the body has a length L2, wherein the ratio of the length L1 to the length L2 is 2:

1 to 10;

1 and wherein the length L1 of the canalicular extension is between 5 and 15 millimeter.

18. The drug delivery devices of claim 15, wherein the glaucoma medicament is travoprost and wherein the silicone operates in conjunction with the at least one pore to release the travoprost at a therapeutically effective dose for period of 60 to 240 days.

22. The drug delivery device of claim 17 wherein the canalicular extension includes a stylus for providing increased stiffness to the canalicular extension.

19. A drug-delivery device comprising:

(a) a body comprising a matrix of a silicone and an ophthalmic drug dispersed throughout the matrix, the body having an outer surface and being configured to be inserted through a punctal aperture and positioned in a punctum or lacrimal canaliculus, wherein the body is a monolithic structure that includes;

i. a shaft portion having a first end and a second end, wherein the shaft portion is configured for insertion through a punctal aperture and positioning in a punctum or lacrimal canaliculus;

ii. a head portion attached to the first end of the shaft portion, wherein the head portion is configured to rest on the exterior of the punctum; and

iii. a distal tip portion attached to the second end of the shaft portion;

(b) a parylene coating covering the outer surface of the body, the parylene coating being substantially impermeable to the drug; and

(c) at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the head portion of the body;

wherein the parylene coating covers all surfaces of the outer surface of the body with the exception of the surface of the head portion exposed by the at least one pore and wherein the ophthalmic drug is travoprost and wherein the silicone operates in conjunction with the at least one pore to release the travoprost at a therapeutically effective dose for period of 60 to 240 days.